FDA red and green lights: June 2025
Controversial nods came for Urogen’s Zusduri and Astra/Daiichi’s Datroway.
Controversial nods came for Urogen’s Zusduri and Astra/Daiichi’s Datroway.
Astra/Daiichi have trumped Gilead’s Trodelvy with a lung cancer approval.
Gilead’s TROP2 ADC sets the bar for Astra/Daiichi’s Datroway in first-line TNBC.
Crunch time approaches for UroGen.
Gilead’s TROP2 ADC prevails in Ascent-04, in first-line PD-L1-positive TNBC.
The group expects to raise nearly $170m.
The company is starting a phase 3 trial of sacituzumab tirumotecan in first-line TNBC.